PainReform’s LayerBio’s Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

Building on previously disclosed progress toward an Investigational New Drug (IND) submission, PainReform and LayerBio are advancing IND-enabling activities, with preparation and development efforts ...
Seeking Alpha

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio’s proprietary drop-less, ...
News Medical

Eli Lilly’s Adverum move: The future of ocular gene therapy at the 4th Ophthalmic Drug Delivery Summit

The race to develop safer, longer lasting, and less invasive treatments is accelerating, and at the heart of that challenge lies drug delivery. Eli Lilly’s move to acquire Adverum Biotechnologies ...
AZoNano

Nanomaterials in Ophthalmology: A Review

Eye diseases are becoming more common. In 2020, over 250 million people had mild vision problems, and 295 million experienced moderate to severe ocular conditions. Delivering therapeutic drugs ...